eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2013
vol. 38
 
Share:
Send email
Share:
abstract:

The expression of membranous complement inhibitors CD46, CD55 and CD59 in the primary and metastatic colon cancer cell lines derived from the same patient

Ewa Wilczek
,
Aleksander Wasiutynski
,
Dariusz Sladowski
,
Grzegorz M. Wilczynski
,
Barbara Gornicka

(Centr Eur J Immunol 2013; 38 (4): 549-555)
DOI: https://doi.org/10.5114/ceji.2013.39774
Online publish date: 2013/12/30
View full text Get citation
 
PlumX metrics:
Membrane-bound complement regulatory proteins protect cells from the complement-based destruction and affects many vital immunological functions. As was shown by many studies, overexpression of these proteins on cancer cells may have a negative influence on the therapeutic effect of monoclonal antibodies and immunotherapy. The most commonly observed complement inhibitors on cancer cells are CD46, CD55 and CD59. In the presented work we evaluated the expression and immunoreactivity pattern of these three regulators in two colon cancer cell lines, one derived from the primary tumor (SW480), and the other from the lymph node metastasis (SW620). Both cell lines were derived from the same patient. We found that in the SW480 cells the expression of all inhibitors was heterogeneous, within this cell line many subpopulations of cells existed, which displayed different levels of complement inhibitors. On the contrary, on SW620 cells the immunoreactivity of examined inhibitors was more homogeneous, virtually all examined cells displayed complement inhibitors immunoreactivity on the same level. The most prominent in both cell lines was the CD46 expression on the cell surface. Our results indicate that during carcinogenesis progression only these cancer cells may spread, migrate and form metastatic foci, which possess more complement inhibitors on their cell surface. Modulation of the function of membrane-bound complement inhibitors may have beneficial influence on such strategies as immunotherapy with monoclonal antibodies.
keywords:

complement inhibitors, colon cancer, metastasis
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.